Viridian Therapeutics, Inc.
VRDN
$28.68
$0.270.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -50.96% | 54.88% | -54.99% | -79.04% | -19.24% |
| Total Depreciation and Amortization | 43.87% | -34.41% | -20.42% | -19.31% | -551.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 136.49% | 90.88% | 22.43% | -1.66% | -71.38% |
| Change in Net Operating Assets | 17,584.57% | -2,132.61% | 42.57% | -179.45% | -91.81% |
| Cash from Operations | 67.61% | -24.97% | -63.65% | -104.88% | -92.98% |
| Capital Expenditure | -110.53% | 56.66% | 59.62% | -- | -137.50% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -440.09% | 249.58% | 22.04% | 170.01% | 62.98% |
| Cash from Investing | -439.49% | 248.91% | 22.17% | 169.95% | 62.93% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 838.64% | -95.29% | 263.81% | -94.98% | -72.62% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -100.00% |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2,489.01% | 98.62% | 100.00% | 98.01% | 88.90% |
| Cash from Financing | 1,042.63% | -95.57% | 607.41% | -94.80% | -82.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 142.43% | -43.53% | -93.08% | 248.59% | -1,048.49% |